anxiety aggravated; swelling of fingers; local swelling; Symptoms of psoriasis got worse on scalp; Could not move; Some problems walking; Moderate pain or discomfort; When she stood up she would faint; Orthostatic hypertension; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of SYNCOPE (When she stood up she would faint), ORTHOSTATIC HYPERTENSION (Orthostatic hypertension), PSORIASIS (Symptoms of psoriasis got worse on scalp), MOBILITY DECREASED (Could not move), GAIT DISTURBANCE (Some problems walking), PAIN (Moderate pain or discomfort), ANXIETY (anxiety aggravated), PERIPHERAL SWELLING (swelling of fingers) and SWELLING (local swelling) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriatic arthritis.    The patient's past medical history included Back disorder NOS (could not lay down on back). Concurrent medical conditions included Swollen joints (swollen joints in hands, wrist, finger, spine), Gait disturbance (some problems walking), Loss of personal independence in daily activities (some problems with usual activities/ sometimes problems with buttons when getting dressed), Pain, Discomfort, Anxiety, Hypertension, Diabetes, Psoriatic arthritis (swollen and tender joints in hands, wrist, finger, spine) and Joint tenderness.   On 26-Feb-2021, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 40 milligram every two weeks. On 22-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In April 2021, the patient experienced SYNCOPE (When she stood up she would faint) (seriousness criteria hospitalization and medically significant), ORTHOSTATIC HYPERTENSION (Orthostatic hypertension) (seriousness criterion hospitalization), PSORIASIS (Symptoms of psoriasis got worse on scalp) (seriousness criterion hospitalization), MOBILITY DECREASED (Could not move) (seriousness criterion hospitalization), GAIT DISTURBANCE (Some problems walking) (seriousness criterion hospitalization) and PAIN (Moderate pain or discomfort) (seriousness criterion hospitalization). On an unknown date, the patient experienced ANXIETY (anxiety aggravated) (seriousness criterion hospitalization), PERIPHERAL SWELLING (swelling of fingers) (seriousness criterion hospitalization) and SWELLING (local swelling) (seriousness criterion hospitalization). The patient was hospitalized from 28-Apr-2021 to 30-Apr-2021 due to ORTHOSTATIC HYPERTENSION and SYNCOPE. At the time of the report, SYNCOPE (When she stood up she would faint), ORTHOSTATIC HYPERTENSION (Orthostatic hypertension), MOBILITY DECREASED (Could not move), GAIT DISTURBANCE (Some problems walking) and PAIN (Moderate pain or discomfort) outcome was unknown, PSORIASIS (Symptoms of psoriasis got worse on scalp) and ANXIETY (anxiety aggravated) had not resolved and PERIPHERAL SWELLING (swelling of fingers) and SWELLING (local swelling) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient's current blood pressure and insulin doses were both decreased after the diagnosis of orthostatic hypertension.  Additional treatments were not provided.   In 2021, the patient reported pain of 4 out of 10 on 1 occasion, and 7 out of 10 on a separate occasion.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.